Home Featured Page 258

Featured

Latest

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul Austin

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

MEC Signs RTO Definitive Agreement To Acquire Albert Labs, A European...

Noetic Launches Second Fund to Invest in Emergent Psychedelic Medicine Sector

Tryp Therapeutics Announces Application to List on OTCQB

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the...

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the...

PsyBio Therapeutics Announces Retention of Market Maker

PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins...

Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics...

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain...

1...257258259...281 Page 258 of 281

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.